Dear Sir, We have recently shown [1, 2] that intranasal glucagon (i. n.-glucagon) was effective in quickly correcting experimentally-induced hypoglycaemia in volunteer diabetic patients. We observed that the i. n.-route initiated a blood glucose rise earlier than did the subcutaneous injection, although the effect of the latter was more sustained. We concluded that i.n.-glucagon was probably a clinically relevant alternative to its parenteral equivalent. We would like to report the results of a controlled study done on diabetic children at a summer camp. Informed consent was obtained from the parents of the children who participated in this study: they accepted that if a severe hypoglycaemic episode occurred it would be treated by glucagon, administered either intranasally or subcutaneously, on a random basis. Twenty consecutive severe hypoglycaemic events (i. e. hypoglycaemic status in which oral glucose administration was judged as impractical or potentially hazardous by the leader of the group, always a medical doctor) occurred spontaneously during leisure activities in 20 young diabetic subjects. As soon as the decision was taken to administer glucagon, a capillary blood glucose determination was done using a glucometer (Glucometer II, Ames-Bayer Diagnostics, Puteaux, France) and Glucostix strips. A box was then opened which randomly contained either a 1 mg glucagon kit for s. c. administration (Novo-Nordisk, Boulogne, France) or an i. n.-glucagon kit (the product to be insufflated into the nostril was made of a lyophylised mixture of 1 mg glucagon + i mg sodium glycocholate (Laboratoires Organn St. Denis, France), as previously described [2] . Blood glucose values were measured at recognition of the hypoglycaemic state (to), then at t + s0 min and t. 30 min; the time which elapsed between the decision to inject and completion of the injection (operating time delay); the time which elapsed until the subject was able to consciously take a glass of orange juice in his hand and drink it (clinical recovery). The results are shown in Table 1 . The main observations which could be drawn from this experience are: (1) that i.n.-glucagon was quickly effective. We observed only one treatment failure with one dose ofi. n.-glucagon in a child who, by mistake, had injected himself with twice the dosage of insulin when an i.v. injection of glucose had to be administered; we also observed one apparent failure with s.c.-glucagon in an epileptic boy whose blood glucose was 60mg at to. (2) i.n.-glucagon was administered more rapidly than s.c.-glucagom although the difference did not reach statistical significance. In any case all the users found the i. m-route much easier to operate. (3) i.n.-glucagon seemed to act at least as rapidly as s.c.-glucagon. However, the increment over 30 min was two-fold greater with i. n.-glucagon although the difference was not significant. If this latter observation is confirmed by further studies involving a larger number of patients, this might be of interest in avoiding overcorrection of hypoglycaemia; this would be consistent with the pharmacological features of i. n. administered glucagon i. e. more rapid onset and shorter action [2, 3] . (4)Side effects (headache, nausea, vomiting) were observed in both groups. This work is the first to demonstrate and quantify the efficiency of i.n.-glucagon in the treatment of hypoglycaemic attacks under pragmatic conditions. Yours sincerely, G. Slama, G. Reach, M. Cahane, C. Quetin and E Villanove-Robin
